4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Enterprise Value data on file, last reported at -$390.9 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 21.61% year-over-year to -$390.9 million in Q1 2026; TTM through Mar 2026 was -$390.9 million, a 21.61% decrease from a year earlier, with the FY2025 full-year figure at -$402.7 million, up 5.23% from the prior year.
• Enterprise Value for Q1 2026 stood at -$390.9 million, up from -$402.7 million in the prior quarter.
• Over the last five years, Enterprise Value for FDMT reached as high as -$200.5 million in Q1 2023 and fell as low as -$541.9 million in Q2 2024.
• Historically, Enterprise Value has averaged -$337.9 million across 5 years, with a median of -$310.3 million in 2023.
• Across the five-year window, Enterprise Value sank 162.36% in 2024 and soared 45.89% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$213.6 million in 2022, then plunged by 34.97% to -$288.2 million in 2023, then tumbled by 47.41% to -$424.9 million in 2024, then gained by 5.23% to -$402.7 million in 2025, then climbed by 2.92% to -$390.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$390.9 million in Q1 2026, -$402.7 million in Q4 2025, and -$305.1 million in Q3 2025.